Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
about
Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Overview: progression-free survival as an endpoint in clinical trials with solid tumors.The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.
P2860
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Impact of disease progression ...... mates in advanced lung cancer.
@en
type
label
Impact of disease progression ...... mates in advanced lung cancer.
@en
prefLabel
Impact of disease progression ...... mates in advanced lung cancer.
@en
P2093
P2860
P356
P1433
P1476
Impact of disease progression ...... mates in advanced lung cancer.
@en
P2093
Alex A Adjei
Katie L Allen Ziegler
Mary W Redman
Shauna L Hillman
Steven E Schild
Sumithra J Mandrekar
Yingwei Qi
P2860
P304
P356
10.1002/CNCR.27528
P407
P577
2012-03-20T00:00:00Z